Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Childhood acute lymphoblastic leukemia
Relapsed and refractory disease after frontline cure rates: blinatumomab, inotuzumab and CD19 CAR-T cells.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:25 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
59
Phase 1 to 3, interventional
For relapsed or refractory disease
36%
21 trial titles name relapsed, refractory or recurrent disease
Led by industry
7%
4 trials with a company as lead sponsor
13 of the 59 childhood acute lymphoblastic leukemia trials are Phase 3; 2 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of childhood acute lymphoblastic leukemia (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 17 of 59 trials name no segment and are listed as Untagged.
Segment:All1L2L+ · Relapsed or refractoryAdvanced or metastaticB-cellB-cell · 2L+ · Relapsed or refractoryB-cell · Relapsed or refractoryCD19 · Relapsed or refractoryCD22Ph+Relapsed or refractoryT-cellT-cell · 1L · Locally advancedT-cell · Relapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedSmall molecule
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Cyclophosphamide Bambino Gesù Hospital and Research Institute | Untagged | Small molecule | Ph2/Ph3 | NCT07297914, NCT00400946, NCT03571321, NCT03286634 +2 |
| methotrexate Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946, NCT03571321, NCT03571321, NCT03286634 +2 |
| cytarabine Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946, NCT03571321, NCT03286634, NCT04043494 +1 |
| Blinatumomab Institute of Hematology & Blood Diseases Hospital, China | B-cell | Antibody | Ph2/Ph3 | NCT06764238, NCT06764238, NCT06882057 |
| Cyclophosphamide National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Small molecule | Ph3 | NCT02101853, NCT03136146, NCT05418088 |
| Mercaptopurine Children's Oncology Group | Untagged | Other or not recognised | Ph3 | NCT01503632, NCT00400946, NCT03571321 |
| Vincristine University of Chicago | Untagged | Other or not recognised | Ph3 | NCT03571321, NCT03286634, NCT04043494 |
| 6-Mercaptopurine National Hospital Organization Nagoya Medical Center | Untagged | Other or not recognised | Ph3 | NCT03286634, NCT04043494 |
| Blinatumomab Charite University, Berlin, Germany | B-cell · Relapsed or refractory | Antibody | Ph3 | NCT07476729, NCT02101853 |
| Cyclophosphamide Dana-Farber Cancer Institute | 1L | Small molecule | Ph3 | NCT03020030, NCT01190930 |
| CYTARABINE Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030, NCT01190930 |
| Daunorubicin National Hospital Organization Nagoya Medical Center | Untagged | Other or not recognised | Ph3 | NCT03286634, NCT04043494 |
| Doxorubicin University of Chicago | Untagged | Other or not recognised | Ph3 | NCT03571321, NCT04043494 |
| etoposide Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946, NCT00641381 |
| Etoposide National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853, NCT03136146 |
| Inotuzumab ozogamicin Charite University, Berlin, Germany | B-cell · Relapsed or refractory | Antibody-drug conjugate | Ph3 | NCT07476729, NCT07770698 |
| LEUCOVORIN CALCIUM Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030, NCT01190930 |
| MERCAPTOPURINE Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030, NCT01190930 |
| METHOTREXATE Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030, NCT01190930 |
| pegaspargase Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946, NCT03571321 |
| Pegaspargase Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030, NCT01190930 |
| Ruxolitinib Bambino Gesù Hospital and Research Institute | Untagged | Small molecule | Ph2/Ph3 | NCT07297914, NCT03571321 |
| therapeutic hydrocortisone Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946, NCT07498465 |
| Thioguanine University of Chicago | Untagged | Other or not recognised | Ph3 | NCT03571321, NCT04043494 |
| asparaginase Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946 |
| Asparaginase National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
| Blinatumomab Bambino Gesù Hospital and Research Institute | Untagged | Antibody | Ph2/Ph3 | NCT07297914 |
| Bortezomib National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Small molecule | Ph3 | NCT02112916 |
| Chemo-light Maintenance 2 Institute of Hematology & Blood Diseases Hospital, China | B-cell | Other or not recognised | Ph2/Ph3 | NCT06882057 |
| Corticosteroids Bambino Gesù Hospital and Research Institute | Untagged | Other or not recognised | Ph2/Ph3 | NCT07297914 |
| Cyclophosphamide National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Small molecule | Ph3 | NCT02112916 |
| Cytarabine National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Cytarabine National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
| Dasatinib Institute of Hematology & Blood Diseases Hospital, China | T-cell | Small molecule | Ph2/Ph3 | NCT06855810 |
| DASATINIB Dana-Farber Cancer Institute | 1L | Small molecule | Ph3 | NCT03020030 |
| Daunorubicin National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Daunorubicin Hydrochloride National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Dexrazoxane Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030 |
| dexrazoxane hydrochloride Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946 |
| Doxorubicin National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Doxorubicin Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030 |
| doxorubicin hydrochloride Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946 |
| Doxorubicin Hydrochloride National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Doxorubicin Hydrochloride Children's Oncology Group | 1L | Other or not recognised | Ph3 | NCT01190930 |
| Erwinia asparaginase Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030 |
| Etoposide National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| ETOPOSIDE Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030 |
| homoharringtonine Institute of Hematology & Blood Diseases Hospital, China | T-cell | Other or not recognised | Ph2/Ph3 | NCT06855810 |
| HYDROCORTISONE Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03020030 |
| Hydrocortisone Sodium Succinate National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Ifosfamide National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Small molecule | Ph3 | NCT02112916 |
| Ifosfamide University Hospital Muenster | Untagged | Small molecule | Ph3 | NCT04043494 |
| leucovorin calcium Dana-Farber Cancer Institute | Untagged | Other or not recognised | Ph3 | NCT00400946 |
| Leucovorin Calcium National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Leucovorin Calcium National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
| Mercaptopurine National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Mercaptopurine National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
| Methotrexate National Cancer Institute (NCI) | T-cell · 1L · Locally advanced | Other or not recognised | Ph3 | NCT02112916 |
| Methotrexate National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
| Mitoxantrone National Cancer Institute (NCI) | B-cell · Relapsed or refractory | Other or not recognised | Ph3 | NCT02101853 |
Showing the 60 most advanced of 191 programs.
Assets over time
59 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | National Cancer Institute (NCI) | |
| Bortezomib | National Cancer Institute (NCI) | |
| Inotuzumab ozogamicin | Charite University, Berlin, Germany | |
| Asparaginase | National Cancer Institute (NCI) | |
| Ruxolitinib | Bambino Gesù Hospital and Research Institute | |
| Blinatumomab | Institute of Hematology & Blood Diseases Hospital, China | |
| Mercaptopurine | Children's Oncology Group | |
| Pegaspargase | Dana-Farber Cancer Institute | |
| olverembatinib | Institute of Hematology & Blood Diseases Hospital, China | |
| Venetoclax | Institute of Hematology & Blood Diseases Hospital, China | |
| Fludarabine | Kara Lynn Davis | |
| busulfan | City of Hope Medical Center | |
| fludarabine phosphate | City of Hope Medical Center | |
| sonrotoclax | BeOne Medicines | |
| pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | |
| ALL, High risk | Jae Wook Lee | |
| Reinduction | Ho Joon Im | |
| Dasatinib(Sprycel) arm | Hyoung Jin Kang | |
| SC-PEG | Dana-Farber Cancer Institute | |
| etoposide | City of Hope Medical Center | |
| Daunorubicin | National Hospital Organization Nagoya Medical Center | |
| autologous CD19-directed chimeric antigen receptor (CAR) T-cells | University of Alberta | |
| Tafasitamab | University Hospital Tuebingen | |
| filgrastim | Masonic Cancer Center, University of Minnesota | |
| clofarabine | City of Hope Medical Center |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07476729 International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) 21 countries, 0% of sites in the US Decision brief → | Ph3 | Charite University, Berlin, Germany | recruiting | 2026-03-17 | 2033-03-31 |
| FORUM2 · NCT07297914 Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL 9 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Bambino Gesù Hospital and Research Institute | recruiting | 2025-12-22 | 2032-11-30 |
| CAMS-Ph+ B-ALL · NCT07152041 Newly-diagnosed Pediatric Ph-positive B-ALL Protocol 2 countries, 0% of sites in the US Decision brief → | Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2025-09-03 | 2029-12 |
| CCCG-LR-B-ALL · NCT06882057 Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol 2 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2025-03-18 | 2029-12-31 |
| CCCG-TALL-2025 · NCT06855810 Newly-diagnosed Pediatric T-cell ALL Protocol 2 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2025-03-04 | 2030-06 |
| CCCG-I/HR-ALL · NCT06764238 Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol 2 countries, 0% of sites in the US Decision brief → | Ph2/Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2025-01-08 | 2029-12-31 |
| LBL 2018 · NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma 21 countries, 0% of sites in the US Decision brief → | Ph3 | University Hospital Muenster | recruiting | 2019-08-02 | 2030-04-22 |
| NCT03020030 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents 2 countries, 78% of sites in the US Decision brief → | Ph3 | Dana-Farber Cancer Institute | active not recruiting | 2017-01-13 | 2026-11-30 |
| NCT02112916 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma 4 countries, 89% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-04-14 | 2020-03-31 |
| NCT02101853 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia 5 countries, 89% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2014-04-02 | 2021-06-30 |
| NCT01503632 Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission 2 countries, 98% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2012-01-04 | 2019-06-30 |
| NCT01190930 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma 7 countries, 88% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2010-08-30 | 2019-03-31 |
| NCT00400946 05-001: Treatment of Acute Lymphoblastic Leukemia in Children 2 countries, 63% of sites in the US Decision brief → | Ph3 | Dana-Farber Cancer Institute | completed | 2006-11-17 | 2014-08 |
| NCT07770698 A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia No sites listed Decision brief → | Ph1/Ph2 | BeOne Medicines | not yet recruiting | 2026-08-18 | 2030-04-30 |
| VHR ALL · NCT06257394 Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea Single-country: South Korea (10 sites) Decision brief → | Ph2 | Hyoung Jin Kang | recruiting | 2024-02-14 | 2034-12-31 |
| HR ALL · NCT06184009 Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia Single-country: South Korea (9 sites) Decision brief → | Ph2 | Jae Wook Lee | recruiting | 2023-12-28 | 2030-12-31 |
| ReCALL · NCT05827549 Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia Single-country: South Korea (10 sites) Decision brief → | Ph2 | Ho Joon Im | recruiting | 2023-04-25 | 2032-12-31 |
| NCT05748171 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL 15 countries, 0% of sites in the US Decision brief → | Ph2 | Pfizer | recruiting | 2023-02-28 | 2033-05-21 |
| NCT05466994 A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) Single-country: United States (2 sites) Decision brief → | Ph2 | M.D. Anderson Cancer Center | completed | 2022-07-20 | 2026-01-13 |
| Anti-CD19-ALL · NCT05366218 Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia Single-country: Germany (11 sites) Decision brief → | Ph1/Ph2 | University Hospital Tuebingen | recruiting | 2022-05-09 | 2028-07 |
| NCT05334823 A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Single-country: China (16 sites) Decision brief → | Ph2 | Chongqing Precision Biotech Co., Ltd | recruiting | 2022-04-19 | 2028-12-31 |
| IDEAL2 · NCT05082519 Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL Single-country: United States (16 sites) Decision brief → | Ph2 | Etan Orgel | recruiting | 2021-10-19 | 2027-08-15 |
| ACIT001/EXC002 · NCT03938987 Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) Single-country: Canada (6 sites) Decision brief → | Ph1/Ph2 | University of Alberta | recruiting | 2019-05-06 | 2026-12 |
| NCT03590171 International Study for Treatment of High Risk Childhood Relapsed ALL 2010 15 countries, 0% of sites in the US Decision brief → | Ph2 | Charite University, Berlin, Germany | recruiting | 2018-07-18 | 2027-12-31 |
| NCT03286634 ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 6 countries, 0% of sites in the US Decision brief → | Ph2 | National Hospital Organization Nagoya Medical Center | active not recruiting | 2017-09-18 | 2028-03-31 |
| NCT03136146 Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2017-05-02 | 2027-08-01 |
| NCT02220985 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Single-country: United States (2 sites) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | completed | 2014-08-20 | 2025-04-01 |
| NCT02094794 Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | active not recruiting | 2014-03-24 | 2027-05-04 |
| NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | completed | 2013-01-04 | 2022-04-15 |
| NCT01574274 SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma 2 countries, 63% of sites in the US Decision brief → | Ph2 | Dana-Farber Cancer Institute | active not recruiting | 2012-04-10 | 2021-07 |
| NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Single-country: United States (1 site) Decision brief → | Ph2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | completed | 2011-06-29 | 2020-11-13 |
| NCT00792948 Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Single-country: United States (157 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2008-11-18 | 2016-06-01 |
| NCT00576979 Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | completed | 2007-12-19 | 2016-05-30 |
| NCT00544115 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders No sites listed Decision brief → | Ph2 | City of Hope Medical Center | active not recruiting | 2007-10-16 | 2007-03-13 |
| NCT00544466 Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | active not recruiting | 2007-10-16 | 2013-08-01 |
| NCT00534430 Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer No sites listed Decision brief → | Ph2 | City of Hope Medical Center | completed | 2007-09-24 | 2010-04-12 |
| NCT00357565 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | Masonic Cancer Center, University of Minnesota | completed | 2006-07-27 | 2024-06 |
| NCT07498465 A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia No sites listed Decision brief → | Ph1 | Children's Oncology Group | withdrawn | 2026-03-27 | 2028-11-12 |
| NCT07257419 CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2025-12-02 | 2031-12 |
| NCT07108868 A Phase I Dose Finding Study of MB-CART2219.1 Single-country: Germany (2 sites) Decision brief → | Ph1 | University Hospital Tuebingen | recruiting | 2025-08-07 | 2027-03 |
| CMD63 · NCT07078929 Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL) Single-country: Thailand (3 sites) Decision brief → | Ph1 | Chulalongkorn University | recruiting | 2025-07-22 | 2026-09-01 |
| NCT06575296 Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant Single-country: United States (1 site) Decision brief → | Ph1 | City of Hope Medical Center | recruiting | 2024-08-28 | 2028-04-29 |
| NCT06326463 CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2024-03-22 | 2030-07-01 |
| NCT06173518 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) 3 countries, 64% of sites in the US Decision brief → | Ph1 | Autolus Limited | recruiting | 2023-12-15 | 2027-11 |
| NCT05857969 Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Single-country: United States (1 site) Decision brief → | Ph1 | Florida International University | recruiting | 2023-05-15 | 2028-02-22 |
| NCT05495035 Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Single-country: China (4 sites) Decision brief → | Ph1 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2022-08-10 | 2026-12-31 |
| NCT05418088 Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Single-country: United States (2 sites) Decision brief → | Ph1 | Sumithira Vasu | recruiting | 2022-06-14 | 2027-07-01 |
| NCT04996160 Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia Single-country: United States (1 site) Decision brief → | Ph1 | Tanja Andrea Gruber | completed | 2021-08-09 | 2023-10-16 |
| NCT04881240 Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | recruiting | 2021-05-11 | 2027-07-01 |
| NCT04088864 CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | Kara Lynn Davis | completed | 2019-09-13 | 2021-11-08 |
| CAR-20/19-T · NCT04049383 CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL Single-country: United States (1 site) Decision brief → | Ph1 | Medical College of Wisconsin | terminated | 2019-08-08 | 2025-06-01 |
| NCT03571321 Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Single-country: United States (2 sites) Decision brief → | Ph1 | University of Chicago | recruiting | 2018-06-27 | 2026-09-01 |
| NCT03326921 HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Single-country: United States (1 site) Decision brief → | Ph1 | Fred Hutchinson Cancer Center | recruiting | 2017-10-31 | 2027-10-16 |
| NCT03241940 Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Single-country: United States (1 site) Decision brief → | Ph1 | Stanford University | active not recruiting | 2017-08-08 | 2025-04-03 |
| NCT02879643 Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy 3 countries, 80% of sites in the US Decision brief → | Ph1 | Therapeutic Advances in Childhood Leukemia Consortium | completed | 2016-08-26 | 2022-07-29 |
| NCT02091245 Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML Single-country: United States (10 sites) Decision brief → | Ph1 | Dana-Farber Cancer Institute | active not recruiting | 2014-03-19 | 2018-02 |
| Vandevol · NCT01279096 Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia Single-country: France (2 sites) Decision brief → | Ph1 | University Hospital, Lille | completed | 2011-01-19 | 2012-06 |
| NCT00641381 Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma Single-country: United States (1 site) Decision brief → | Ph1 | City of Hope Medical Center | completed | 2008-03-24 | 2026-02-13 |
| NCT00641030 Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes Single-country: United States (1 site) Decision brief → | Ph1 | City of Hope Medical Center | completed | 2008-03-21 | 2011-01-01 |